What happens when you put twenty unreasonably accomplished people in a room with extraordinary wine and ask them what the rest of us are missing?
We’ve done our best to bring you inside exactly such an evening. We wrote most of this on the flight back to San Francisco, while it was still fresh.
There’s a moment at every dinner we host when we look around the table and think: how did this happen? Not existentially. In a grateful, slightly disbelieving way. The moment you realize you’ve pulled off something that shouldn’t work on paper, because the people in the room have no business being in the same room.
A Master Sommelier. The dean of a top medical school. A gene-editing pioneer. A tech founder who built a billion-dollar company and then showed up to a wine dinner to cheerfully predict the end of organizational hierarchies as we know them. An infectious disease specialist who tracks diseases migrating north from South America with the measured calm of someone who has seen too much to be surprised by anything.
The common thread isn’t discipline, it’s curiosity. These are people who stand at the shoreline rather than retreating to the safe high ground. The waves are crashing, the sand is shifting, and they lean in.
We gathered in a small Boston restaurant on an otherwise unremarkable Tuesday. The chef was quietly doing extraordinary things with chestnuts and red wine in the kitchen. Our sommelier was describing bottles with more reverence than we ended up showing them, which is the highest possible compliment. And around the table, a conversation unfolded that moved from the structure of organizations to the structure of human aging to, eventually, the history of imperial wine orders.
Welcome to the table.
The Room
There were physicians who run hospitals and physicians who run labs. There were investors who read clinical trial data the way a cardiologist reads an EKG: fast, pattern-first, with an immediate sense of what the numbers are saying versus what the press release wants you to believe. There was a journalist who spends days in the gap between what medicine knows and what patients can access, and finds that gap wider than it should be. There were scientists working on genes, on aging, on the mind, on the skin. There were entrepreneurs and a professor who literally wrote the book on what makes teams work.
There were also two undergraduates, which matters. Every dinner needs someone who hasn’t yet decided what to be certain about.
We won’t name anyone. We observe Chatham House rule, which is a fancy way of saying: what’s said at the table stays at the table, but the ideas are fair game.
The Setting
Our Master Sommelier treated wine as geography and philosophy rather than just bottles. He described each pour as a small lesson in how soil, slope, and decision-making produce something irreplaceable. The evening closed with a dessert wine that was once a standing order for Russian tsars and admired by Napoleon, Jane Austen, and Dickens. When he poured it, the room went quiet for a moment, which at this table is meaningful.
The Prompt: What’s the One Big Thing Nobody Is Talking About?
Midway through dinner, we put a question to the table. What are you seeing in your world that you think is genuinely important, and that you don’t think anyone else is really noticing?
The answers were not what you’d hear at a conference.
The mutation nobody is telling you about.
A stem cell biologist went first. As we age, a small fraction of our blood cells pick up mutations. Those mutated cells don’t announce themselves. They multiply quietly over decades. By the time they become a problem, they’ve been a problem for a long time without your knowledge. And they drive a low-grade inflammation that shows up downstream as many of the diseases we blame on aging: heart attacks, certain cancers, Alzheimer’s.
His point, made with the enthusiasm of someone who has been sitting on this while the rest of medicine catches up, was that aging is not just wear and tear. It’s partly a mutation problem. If you can spot those mutated cells early and clear them out, you might not stop aging exactly, but you could stop the diseases that kill people during aging. His goal, stated with disarming bluntness: live long, die fast. A long functional life followed by a quick exit. No slow unraveling.
The vaccine that should have happened in the hospital
An infectious disease specialist raised something that sounds simple and is not. We are terrible at vaccinating people while they’re in the hospital. The payment structure assigns vaccination to primary care, so the hospital isn’t reimbursed for it. Patients who are already in a medical setting, already in contact with providers, leave without the vaccines that would protect them from shingles, flu, or pneumonia. When a patient is most accessible, the system is least organized to help them.
The frustrating part is that during COVID, hospitals briefly did this correctly. Vaccination became part of the discharge process, built into the standard order set. Then the urgency passed and the system reverted. The infrastructure existed, it worked, and we let it go.
The gap between clinical rigor and the patient in front of you
A veteran health journalist raised the question of what happens to people who fall between clinical trials. The randomized controlled trial is the gold standard of evidence. It is also inaccessible, geographically restricted, tightly enrolled, and often built around populations that don’t include the patient sitting across from you in the exam room.
This opened the most sustained argument of the evening. A healthcare investor pushed back with precision. The double-blind trial earns its reputation when effect sizes are small and noise is high. When a drug is genuinely effective, you often don’t need the full apparatus. But most drugs are presented with more confidence than the evidence warrants, which is why the standard still matters. The guest walked us through a now-famous cancer drug whose original data was modest; only through the accumulation of later trials did it become the poster child for targeted therapy. The treatment effect wasn’t obvious at the start. It emerged.
Another guest pointed out that the insurance question changes everything. If a payer is covering an expensive drug, rigorous evidence is a reasonable requirement. But for treatments that are cash-pay and mostly about optimization rather than curing disease, the question is whether the same standard applies or whether we should build better data infrastructure around what people are already doing.
One of the tech founders offered a provocation: if the FDA regulated smartphones the way it regulates drugs, we’d all still be using flip phones. The table was not fully sold. It was also not fully dismissive. The professor challenged further, asking in light of all the misinformation, anxiety and isolation stemming from a smart phone society, would regulation until we had outcome data have been a bad thing? That’s the right posture for a question with no clean answer.
The most dangerous people in gene editing are not in academia
A pioneer in precision gene editing spends days working on serious inherited diseases. The guest has also, somewhat reluctantly, become aware of a parallel conversation happening in well-funded corners of the tech world about using embryonic gene editing not to treat disease but to engineer children. Enhanced bone density for space travel. Selected physical traits. The science does not support any of this yet. Complex traits like intelligence are shaped by thousands of genes we don’t understand well enough to target, and anyone claiming otherwise is selling something.
But the infrastructure is being built. The money is being spent. And the people spending it are not engaging with the scientific or ethical community in good faith. They are building a public narrative first.
The guest’s sharpest observation was about language. When these projects use the word enhancement, they colonize a term that scientists also use, and they use it to mean something entirely different. Once a meme attaches to a word, it’s very hard to get the word back.
Scientists working on genuine disease prevention find themselves sharing vocabulary with people engineering children for commercial purposes. And because scientists are, as a group, genuinely terrible at Instagram, they’re losing the narrative.
A medical school dean offered the most important clarification of the evening. The ethics at the hard end of the spectrum are not complicated. If a disease is severe, highly predictable from a single gene, and the edit is safe, the case for fixing it is similar to the case for a vaccine. The hard questions arise when the evidence is murky, the trait is complex, and the people driving the demand are wealthy and unaffiliated with the medical system.
The leadership vacuum nobody wants to name
A business school professor didn’t describe a technology or a disease, buta pattern. We’ve drifted from a model of leadership as service toward a model of leadership as personal achievement. The shift has happened so gradually that most institutions absorbed each step without registering the cumulative drift. We’ve not only gotten used to bad leadership, we’ve started to celebrate it, mistaking the accumulation of personal power for the exercise of responsibility.
She offered no names because she didn’t need to. Everyone at the table filled in their own.
Her point was that leadership is about directing collective effort toward a shared purpose. When someone treats an organization as a vehicle for their own elevation, it doesn’t just fail that organization. It degrades the concept itself. And because social media has built a very loud broadcast channel for exactly that style of self-presentation, we’ve created a feedback loop that rewards the wrong things.
The shape of aging is not what we think it is
An aging researcher arrived with a critique of the entire taxonomy of medicine. We organize our research, our treatment, our funding, and our hospital systems around diseases. There is a department of cardiology, a cancer center, a diabetes clinic. But the master variable underneath all of them is aging itself. Organs age at different rates. Weak links fail first. What we call diseases are the local expressions of a system-wide process that we’ve declined to study as a system.
Why do we organize medicine around diseases rather than around the biology that produces most of them? Partly history. Partly structure. Partly because aging as a research target lacks the specificity that funders and institutions prefer. You can’t exactly treat aging. You can only understand it well enough to intervene at the right points at the right times.
Something is coming up from the South
An infectious disease specialist has spent thirty decades studying a parasitic disease transmitted by an insect that most Americans have never heard of. They have now identified that insect in New Jersey. The parasite is present in wild animals along the southern border of the United States. Cases have been found in Louisiana, Texas, Arizona, California.
The guest delivered this information with the equanimity of someone who knew it was coming. Climate change is not a future threat to the geography of infectious disease. It is current. The range of disease-carrying insects is moving north. What was a South American problem is becoming a North American one, and the surveillance system is not ready.
The organizational chart is a Roman legion
One of the tech founders spent a cheerful stretch arguing that the pyramid structure of organizations, essentially unchanged since the Roman legion, is about to be disrupted by something with no real precedent in institutional history.
His observation wasn’t that AI will do jobs. It’s that AI is becoming recursive: the top labs are using AI to write the software that improves the AI that writes more software. The slope is steepening. His companies are already planning on month-by-month horizons rather than annual ones, because the two-year landscape is too uncertain to plan for the old way.
The implication for organizations, he argued, is that the pyramid is becoming obsolete. Decisions used to flow down from centralized intelligence at the top. What he see replacing it looks like a circle: an AI system at the center holding full organizational context, with humans working around it in roles defined by relationship, judgment, and taste rather than by specialized knowledge the AI already holds.
A private equity investor pushed back. The advantage in organizational competition won’t come from the training data or the model, which will be available to everyone. It will come from relationships, track records, and the irreducibly human capacity to pick up the phone and close a deal. The person who has already built trust over thirty years, who knows what doesn’t work, has an advantage a database cannot replicate.The quantum physicist added that the real IP is in the data not published and therefore unavailable to public LLMs. Knowing what did not work is the competitive advantage.
The founder’s response was that he agreed, which was unexpected, and that the two of them had been talking about different things. The relationship is the non-digital human factor. That’s not data. That’s the last thing the AI touches.
Circumambulation
Late in the evening, after the dessert wine had been opened, after the most famous red had run out, and after the table had reached the state of mild incoherence that comes from good food and too many ideas, we brought up a word we love: circumambulation. It’s a Jungian concept. You understand something by walking around it rather than attacking it directly.
The best conversations work this way. You don’t get to the real question by going straight at it. You arrive through the stem cells, through the vaccine reimbursement problem, through the gene-editing ethics hearing, through the sommelier’s story about a wine that once traveled under armed escort to the Russian court. And somewhere between one course and the next, between the argument about clinical trials and the argument about artificial intelligence, you find yourself understanding something you didn’t know you were looking for.
That’s what these dinners are for. Not the wine, though the wine was extraordinary. Not the credentials, though the credentials in that room were absurd. It’s the interface, the place where one thing meets another and something new becomes possible.
To give you a glimpse of the magic: a world-renowned infectious disease specialist quietly turned the menu into a scratchpad over the course of the evening, intermingling tasting notes from the sommelier with insights from every corner of the table. It was a work of intellectual art, a glimpse into how a brilliant mind becomes brilliant and what’s possible when you bring this kind of community together.
The waves are still crashing. The sand is still shifting. The right people are still standing at the shoreline.
A special thank you to Private Medical for co-hosting the evening.
This room earned its evening. The connections made here are the whole point. We hope they stick.